Winston Pharmaceuticals, Inc.
WPHM · OTC
3/31/2010 | 12/31/2009 | 9/30/2009 | 6/30/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -12.71% | 0.00% | -16.19% | -21.42% |
| EV / EBITDA | -13.69 | 2.79 | -3.97 | -2.69 |
| Quality | ||||
| ROIC | -707.53% | -115.07% | -69.91% | -40.97% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.92 | 1.36 | 1.18 | 1.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 70.84% | 71.81% | 72.08% | 56.67% |
| Free Cash Flow Growth | -15.80% | 7.47% | 22.70% | 30.60% |
| Safety | ||||
| Net Debt / EBITDA | 1.47 | 2.79 | 3.31 | 4.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 10.10 | 13.68 | 22.75 |